Levetiracetam Hospira (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, modulating calcium‑dependent neurotransmitter release. This stabilizes neuronal firing and reduces the hyper‑excitability that underlies seizure activity.

The dosing regimen for Levetiracetam Hospira is determined by the prescribing clinician based on the patient’s age, weight, renal function and seizure type. No fixed dose is provided here; the prescriber sets the appropriate infusion rate and total daily amount.

Levetiracetam is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the risk. Limited data are available for breastfeeding, so clinicians should weigh benefits against possible exposure to the infant.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Levetiracetam offers a favorable safety profile and minimal drug‑enzyme interactions compared with older agents such as phenytoin or carbamazepine. It does not require routine serum level monitoring and is less likely to cause hepatic enzyme induction, making it a convenient option for intravenous seizure management.

Levetiracetam Hospira should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the solution. Once removed from refrigeration, use within the time frame specified in the product labeling and keep the vial in its original packaging.

The product is supplied as an intravenous solution that is administered by slow infusion into a vein, typically over 15 minutes to several hours depending on the clinical protocol. Administration should be performed by qualified healthcare personnel in a setting equipped for IV therapy.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, blood dyscrasias (e.g., neutropenia), significant mood disturbances including depression or suicidal thoughts, and rare cases of hepatic dysfunction. Prompt medical attention is required if any of these events occur.

Patients with known hypersensitivity to levetiracetam or any component of the formulation should avoid its use. Caution is also advised for individuals with severe renal impairment, as dose adjustment may be required, and for those with a history of serious psychiatric disorders.